No Data
No Data
Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Gain Therapeutics Advances Parkinson's Therapy Development
Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease
Gain Therapeutics | 8-K: Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Unlock the Full List